The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Hannah Linden on Management of ER-Positive Metastatic Breast Cancer After CDK4/6 Inhibitor Therapy
By The Cancer News Team
Dr. Hannah Linden reviews treatment strategies for ER-positive metastatic breast cancer after CDK4/6 inhibitors, highlighting SERDs, combination therapies, ESR1 mutation testing, and emerging imaging tools.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Vidhya Nair on De-escalation and Personalized Treatment in HER2-Positive Breast Cancer
By The Cancer News Team
Dr. Vidhya Nair reviews key advances in HER2-positive breast cancer, highlighting de-escalation in early-stage disease, T-DXd in high-risk and metastatic settings, and evolving personalized treatment strategies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
Dr. Xiaowen Wang on Optimizing Patient Selection in Advanced ER-Positive Breast Cancer
By The Cancer News Team
Dr. Xiaowen Wang reviews evolving strategies for advanced ER-positive metastatic breast cancer, highlighting NGS timing, ESR1 and PIK3CA mutations, novel SERDs, and targeted combination therapies.
What Is Metastatic Cancer? Understanding When and How Cancer Spreads
By Dr. Chandra Lalita Kakarala
What metastatic cancer means, how cancer spreads through lymph nodes and blood, common sites of metastasis, symptoms, diagnosis, and modern treatment options for stage 4 cancer.
What Is Metastatic Cancer? Understanding When and How Cancer Spreads
By Dr. Chandra Lalita Kakarala
What metastatic cancer means, how cancer spreads through lymph nodes and blood, common sites of metastasis, symptoms, diagnosis, and modern treatment options for stage 4 cancer.
What Is Metastatic Cancer? Understanding When and How Cancer Spreads
By Dr. Chandra Lalita Kakarala
What metastatic cancer means, how cancer spreads through lymph nodes and blood, common sites of metastasis, symptoms, diagnosis, and modern treatment options for stage 4 cancer.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Ning Dong on Clinical Updates on Classification, Treatment, and Emerging Trials of T-Cell Lymphoma
By The Cancer News Team
Dr. Ning Dong reviews updated WHO classification, frontline and relapsed treatment strategies, prognostic modeling in advanced cutaneous T-cell lymphoma, and promising phase 2 trials including CD5 CAR T therapy.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. Sioban B. Keel on Germline Cancer Predisposition in Myeloid Malignancies
By The Cancer News Team
Dr. Sioban B. Keel reviews germline cancer predisposition in myeloid malignancies, highlighting DDX41, donor selection, somatic mosaicism, and how inherited risk reshapes diagnosis, monitoring, and transplant decisions.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. L. Christine Fang on Modern De-Escalation in Breast Cancer Radiation Therapy
By The Cancer News Team
Dr. L. Christine Fang reviews modern de-escalation strategies in breast cancer radiation therapy, including hypofractionation, partial breast irradiation, and radiation omission for selected patients.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Vivian G Oehler on Advances in Myeloproliferative Neoplasm Treatment
By The Cancer News Team
Dr. Vivian G. Oehler reviews major advances in myeloproliferative neoplasms, including pelabresib in myelofibrosis, CALR-targeted therapy in essential thrombocythemia, rusfertide in polycythemia vera, and new allosteric inhibitors in CML.
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Ryan Cassaday on Recent Advances in the Treatment of Acute Lymphoblastic Leukemia
By The Cancer News Team
Dr. Ryan Cassaday reviews chemotherapy-free frontline strategies, MRD risk stratification, CAR T-cell consolidation, and transplant decision-making in adult acute lymphoblastic leukemia (ALL).
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.
Dr. Mwanasha Hamuza Merrill on Frontline and Emerging Treatment Strategies for Chronic Lymphocytic Leukemia
By The Cancer News Team
At Best of Hematology & Breast Cancer 2026, Dr. Mwanasha Hamuza Merrill reviews frontline and emerging treatment strategies for chronic lymphocytic leukemia, highlighting CLL17, BRUIN 314, and novel BTK degrader data.